

BLISS GVS PHARMA LIMITED
 Regd Office, 102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
 CIN: L24230MH1984PLC034771
UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30.06.2015

PART - I

SR. NO.	PARTICULARS	(Rs.in Lacs)			
		STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2015 (UNAUDITED)	31.03.2015 (UNAUDITED)	30.06.2014 (UNAUDITED)	31.03.2015 (AUDITED)
1	INCOME FROM OPERATIONS				
	(a) NET SALES (NET OF EXCISE DUTY)	7,982.83	6,796.32	6,980.88	30,945.89
	(b) OTHER OPERATING INCOME	42.06	68.51	51.55	356.28
	TOTAL INCOME FROM OPERATIONS(NET)	8,024.88	6,864.83	7,032.43	31,302.17
2	EXPENSES				
	a) CONSUMPTION OF RAW MATERIALS	3,483.87	2,946.33	2,582.48	13,784.13
	b) PURCHASE OF TRADED GOODS	36.37	-	-	90.32
	c) (INCREASE)/DECREASE IN STOCK IN TRADE	15.90	113.10	292.53	248.27
	d) EMPLOYEE BENEFIT EXPENSES	482.58	469.38	394.18	1,736.08
	e) DEPRECIATION / AMORTISATION	135.22	145.07	112.93	507.83
	f) OTHER EXPENDITURE	1,577.41	2,040.08	1,672.74	6,823.95
	TOTAL EXPENSES	5,731.34	5,713.96	5,054.86	23,190.58
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)	2,293.55	1,150.87	1,977.57	8,111.59
4	OTHER INCOME	630.78	213.17	304.44	2,135.03
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)	2,924.33	1,364.04	2,282.01	10,246.63
6	FINANCE COST	291.18	296.42	223.97	1,121.18
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)	2,633.15	1,067.61	2,058.04	9,125.45
8	EXCEPTIONAL ITEMS				
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	2,633.15	1,067.61	2,058.04	9,125.45
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1,092.90	421.51	658.57	3,123.90
11	NET PROFIT FOR THE PERIOD (9 - 10)	1,540.25	646.10	1,399.47	6,001.55
12	PAID - UP EQUITY CAPITAL	1,031.47	1,031.47	1,031.47	1,031.47
13	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				35,787.14
14	BASIC AND DILUTED EPS (NOT ANNUALISED)	1.49	0.63	1.36	5.82

PART - II

	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2015 (UNAUDITED)	31.03.2015 (UNAUDITED)	30.06.2014 (UNAUDITED)	31.03.2015 (AUDITED)
A	PARTICULARS OF SHAREHOLDING				
1	AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS.1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05
2	PROMOTER AND PROMOTER GROUP SHAREHOLDING				
	A) PLEDGE/ ENCUMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)				
	B) NON - ENCUMBERED - NO. OF SHARES (FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95	66989830 100.00 64.95

	Particulars	Quarter ended 30th June 2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	8
	Received during the quarter	6
	Disposed off during the quarter	14
	REMAINING UNSOLVED AT THE END OF THE QUARTER	0

NOTES:-

1. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON AUGUST 14TH 2015
2. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
3. DURING THE QUARTER THE COMPANY HAS ACQUIRED 51.51% EQUITY SHARES OF SHREE SALES PACK PVT LTD WHICH IS ENGAGED IN THE BUSINESS OF PRINTING OF PACKING MATERIAL WHICH HAS BECOME THE SUBSIDIARY OF THE COMPANY.
4. DURING THE QUARTER, THE COMPANY HAS SOLD THE INVESTMENT IN ITS STEP DOWN SUBSIDIARY NAMED SURGIMED PHARMA LIMITED.
5. TAX EXPENSES INCLUDES AN AMOUNT OF RS. 153.15 LACS PERTAINING TO INTEREST PAYABLE ON TAX EXPENSE OF PREVIOUS FINANCIAL YEAR
6. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2015 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2014.
7. PREVIOUS YEAR/PERIOD FIGURES ARE REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
DATE : 14TH AUGUST 2015

For BLISS GVS PHARMA LIMITED

SD/-
S. N. KAMATH
MANAGING DIRECTOR

Limited Review Report

The Board of Directors
Bliss GVS Pharma Limited

We have reviewed the accompanying statement of standalone unaudited financial results of Bliss GVS Pharma Limited for the quarter ended June 30, 2015 ("the Statement") except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures, made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results for the quarter ended June 30, 2015 prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in and loans given to two of its subsidiaries [net of the amount realisable on disposal of a step down subsidiary (see Note 4)] aggregating Rs 7,306 lakhs.

Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W



Himanshu Chapsey
Partner
Membership No. 105731
Mumbai, August 14, 2015



Pune

T | 91 020 60601005/6/7/8/9
F | 91 020 25666932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru

T | 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi

T + 91 011 4182 8360
E bkkdelhi@bkkhareco.com
107, Siddharth Chambers,
Near IIT Gate,
Kalu Sarai, Hauz Khas,
New Delhi - 110 016, India.